Jeffrey Foy, PhD, Senior Director, Toxicology, Dicerna Pharmaceuticals

Jeff Foy is the Senior Director of Toxicology at Dicerna Pharmaceuticals located in Lexington Massachusetts. He is responsible for the design and conduct of toxicology studies and authoring of nonclinical regulatory submissions for Dicerna’s GalXC platform of compounds which are GalNAc-conjugated double-stranded siRNAs. He also manages the nonclinical writing group at Dicerna. Prior to joining Dicerna, Jeff worked at Celgene where he worked on small molecules and biologics for oncology and severe inflammatory diseases. He received his PhD in toxicology from Northeastern University in Boston. Jeff also chairs the oligonucleotide safety working group (OSWG).

Jeffrey Foy, PhD, Senior Director, Toxicology, Dicerna Pharmaceuticals

Jeff Foy is the Senior Director of Toxicology at Dicerna Pharmaceuticals located in Lexington Massachusetts. He is responsible for the design and conduct of toxicology studies and authoring of nonclinical regulatory submissions for Dicerna’s GalXC platform of compounds which are GalNAc-conjugated double-stranded siRNAs. He also manages the nonclinical writing group at Dicerna. Prior to joining Dicerna, Jeff worked at Celgene where he worked on small molecules and biologics for oncology and severe inflammatory diseases. He received his PhD in toxicology from Northeastern University in Boston. Jeff also chairs the oligonucleotide safety working group (OSWG).

John Davis II, PhD, Vice President, Head of Preclinical Development, Dyne Therapeutics

John Davis is presently Vice President, Head of Preclinical Development at Dyne Therapeutics, a genetic medicine company located in Waltham, MA, and is responsible for developing preclinical strategies necessary for underwriting clinical trials from First In Human through Phase III. John has close to 20 years of experience in a global biopharmaceutical setting with expertise in managing both exploratory and GLP nonclinical toxicology studies; utilizing both internal and external resources. John’s breadth of portfolio support includes antisense oligonucleotide, small molecule and biologic programs. Prior to joining Dyne, John was Vice President of Preclinical Development at Wave Life Sciences where he established toxicology as a core discipline including leading cross-functional teams aimed at developing and implementing early safety screening strategies. Prior to Wave, John held positions of increasing responsibility at first Schering-Plough and then Pfizer. While at Pfizer, John was a recognized leader in developing mechanism-based human risk assessment projects and led highly effective cross-discipline teams utilizing demanding novel approaches. John has co-authored more than 20 peer-reviewed publications and reviews and has given numerous invited seminars at both scientific meetings as well as academic institutions. John has co-chaired multiple continuing education courses, symposia and workshops at both annual Society of Toxicology (SOT) and American College of Toxicology (ACT) meetings, and is a founding/charter member of the Drug Discovery Toxicology Specialty Section of SOT where he has served as the secretary/treasurer and president and was a member of the SOT Congressional Task Force. He has also participated in multiple industry-wide consortiums including the nephrotoxicity working group of the ILSI-HESI toxicogenomics group and the Critical Path Initiative’s nephrotoxicity biomarkers working group. John recently completed a 6-year term as an Associate Editor for the journal Toxicology and Applied Pharmacology and is a charter and current member of the University of Wisconsin Undergraduate Pharm/Tox External Advisory Board.

Xiao Shelley Hu, Senior Director, Head of DMPK and Clinical Pharmacology, Wave Life Sciences

Dr. Xiao Shelley Hu, Ph.D., is a Senior Director at Wave Life Sciences in Boston, currently the head of the DMPK and Clinical Pharmacology department. Her group is responsible for ADME, PK/PD, and Pharmacometric studies in preclinical and clinical stages in neuromuscular, CNS, and hepatic diseases. Prior to joining Wave Life Sciences, she was a Director at Akebia Therapeutics in Boston, leading the Clinical Pharmacology, Pharmacometrics and Bioanalytical function. Shelley joined Akebia from Biogen, where her responsibility evolved from pre-clinical DMPK to Clinical Pharmacology, and later to Pharmacometrics for both small molecules and large molecules from discovery to post-market in Neurology, Rheumatology, Oncology, and Immunology. Shelley received her Ph.D. in Pharmaceutical Sciences from the Ohio State University, M.S in Pharmaceutical Sciences from the Ohio State University, M.S. in Environmental Chemistry from Chinese Academy of Sciences, and B.S. in Pharmaceutical Sciences from Peking University Health Science Center. She has fourteen publications in peer-reviewed journals and one book chapter and serves as reviewers for various journals.